

# **Company Flash**

19 February 2007 | 6 pages

# ABB(India) (ABB.BO)

## Buy: Another Strong Quarter, PAT Up 43% YoY

- PAT up 43% YoY ABB (India) 4QCY06 PAT at Rs1.35bn (up 43% YoY) was 7% ahead of CIR estimate of Rs1.26bn on faster execution of orders leading to net sales of Rs14.3bn, which was 5% ahead of CIR estimates. CY06 PAT of Rs3.4bn (up 56% YoY) was 3% ahead of CIR estimate of Rs3.3bn.
- Strong order inflow momentum ABB (India) booked Rs14.1bn (up 40% YoY) of fresh orders in 4QCY06, ending the year with an order backlog of Rs33.7bn (up 60% YoY). In CY06, the company booked orders worth Rs56.2bn (up 50% YoY). Strong industrial growth and power capex imply future order inflows.
- Power capex: stronger for longer The power capex cycle will be stronger for longer as the first concrete numbers of the Ministry of Power's (MoP) generation targets for the XIIth Plan (FY12-17E) at 86.5GW has started trickling in, implying that capacity addition targets in the 10 years from FY07E-FY17E is likely to be 153.5GW, up 89% vis-à-vis that in FY97A-FY07E
- Peak utilizations drive corporate capex India's industrial capex is set to take off driven by (1) a strong macroeconomic tail-wind, (2) peak industry utilizations and (3) strong corporate balance sheets. According to CRISINFAC, industrial capex is set grow 181% in FY06-10, up 181% over that in FY99-FY05.
- Maintain Buy/Low Risk rating —Our target price of Rs4,400 is based on a P/E of 34.7x FY08E which is a ~50% premium to BHEL, in line with the premium over the last 3 years.

#### Figure 1. ABB Statistical Abstract

Year to	Net Profit	EPS	EPS Growth	P/E	EV / EBITDA	P / Book	ROE	DPS	Div. Yield
31-Dec	(Rsmn)	(Rs)	(%)	(x)	(x)	(X)	(%)	(Rs)	(%)
CY05	2,187	51.60	45.28%	73.7	49.4	18.1	27.4%	8.00	0.2%
CY06E	3,316	78.24	51.64%	48.6	33.4	13.7	32.1%	9.00	0.2%
CY07E	4,845	114.32	46.11%	33.2	22.0	9.9	34.6%	10.00	0.3%
CY08E	6,943	163.82	43.30%	23.2	14.9	7.1	35.6%	11.00	0.3%
CY09E	9,159	216.10	31.91%	17.6	11.1	5.1	33.7%	12.00	0.3%

Source: Citigroup Investment Research

See Appendix A-1 for Analyst Certification and important disclosures.

Buy/Low Risk	1L
Price (15 Feb 07)	Rs3,800.95
Target price	Rs4,400.00
Expected share price return	15.8%
Expected dividend yield	0.2%
Expected total return	16.0%
Market Cap	Rs161,091M
	US\$3,671M

#### Venkatesh Balasubramaniam<sup>1</sup>

+91-22-6631-9864 venkatesh.balasubramaniam@citigroup.com

#### Deepal Delivala<sup>1</sup>

+91-22-6631-9857 deepal.delivala@citigroup.com

Pankaj Sharma<sup>1</sup> pankaj4.sharma@citigroup.com

<sup>1</sup>Citigroup Global Market India Private Limited

Citigroup Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD.

#### Figure 2. ABB 4QCY06 Results

r End Dec31 (Rsmn)	4QCY05	4QCY06	% Chg	4QCY06E	% Chg	Remarks
er Backlog	21,032	33,723	60.3%			
er Inflow	10,166	14,126	39.0%			
Sales	9,857	14,263	44.7%	13,545	37.4%	Sale 5% ahead of CIR estimates
)/Dec in Stock in Trade	(165)	(71)				
<i>i</i> materials	(6,850)	(10,431)	52.3%	(9,888)	44.4%	
a % of net sales	71.2%	73.6%		73.0%		
if Cost	(493)	(657)	33.4%	(625)	26.7%	
a % of net sales	5.0%	4.6%		4.6%		
er Expenditure	(957)	(1,157)	20.9%	(1,219)	27.3%	
a % of net sales	9.7%	8.1%		9.0%		
al Expenditure	(8,466)	(12,316)	45.5%	(11,732)	38.6%	
rda	1,392	1,947	39.9%	1,814	30.3%	
TDA margin%	14.1%	13.6%		13.4%		Marginally better than expectations
reciation	(62)	(71)	14.8%	(69)	11.3%	
Г	1,330	1,876	41.1%	1,745	31.2%	
l margin%	13.5%	13.1%		12.9%		
rest	(26)	(1)	-95.9%	(2)	-90.7%	
er Income	159	174	9.4%	200	25.8%	
	1,462	2,049	40.1%	1,942	32.8%	
margin%	14.8%	14.4%		14.3%		
	(516)	(699)	35.5%	(680)	31.7%	
ctive Tax Rate%	35.3%	34.1%		35.0%		
	946	1,350	42.6%	1,262	33.4%	PAT 7% ahead of CIR estimates
urring PAT margin%	9.6%	9.5%		9.3%		

Source: Citigroup Investment Research

# ABB(India)

#### Company description

ABB is a global provider of power transmission and distribution (T&D) products and automation technologies to utility and industry customers. The ABB group operates in over 100 countries and employs about 104,000 people. ABB India employs over 4000 people, has 10 manufacturing units, is a global engineering and operations centre and is a group corporate R&D facility. The company has a countrywide marketing and service presence spanning 27 marketing offices, a network of over 650 channel partners and 8 service centres. Traditionally, ABB had 2 divisions — power technologies and automation technologies. But from January 1, 2006 the ABB group was restructured into 5 divisions for better management and control, and ABB India adopted the same five-division structure.

## Investment thesis

We rate ABB India Buy/Low Risk. Our rating is supported by our positive views on: i) *Power capex* in India, given GDP growth of 8%-plus, government support for adding generation capacity and a massive rural electrification programme; ii) *Industrial capex* in India, which CRISINFAC sees as increasing to Rs4,326bn in FY06-10, up 181% from Rs1,541bn in FY99-FY05; iii) *ABB India's increasing* 

*importance in the ABB Group*, with India not only a promising domestic market but also a key regional and global resource base; iv) *ABB India's access to parent technology;* v) *EPS growth*, being one of the highest in our Indian industrials universe at 40% over CY06-09E; vi) *RoEs* (in the 32 -36% band over the next 4 years) and *positive free cash flows*.

#### Valuation

Our target price for ABB of Rs4,400 is based on 34.7x FY08E EPS, and is set at ~ 50% premium to our target FY08E P/E multiple of 23x for BHEL. ABB has traded at average premium of ~ 50%+ to BHEL for the last three years, a premium that actually narrowed in CY03 – CY06, compared to CY99 – CY03, as BHEL re-rated significantly. ABB has also traded at an average premium of 85%+ to the BSE Sensex over the last three years. At our target price, ABB would trade at 26.9x CY08E EPS and 20.4x CY09E EPS.

#### Risk

3

Our quantitative risk-rating system, which tracks 260-day historical share price volatility, assigns a Medium Risk rating to ABB India. However, we believe a Low Risk rating is more appropriate given that strong power and industrial capex in India provides ABB with significantly visibility on order inflows and that ABB is India's market leader in the power and automation space. Our Low Risk rating is also in line with that of BHEL.

The key downside risks to our positive view on ABB India include the following: (a) Increased competition; (b) Slowdown in investments in generation, transmission and distribution (c) Slowdown in the industrial capex cycle; (d) Substantial increase in input prices; (e) Employee retention.

### **Other Companies: Valuation and Risks**

#### Bharat Heavy (BHEL.BO, Rs2,386, Buy/Low Risk)

**Valuation**: Our target price for BHEL is Rs2,764. Our target P/E multiple of 23x FY08E EPS is based on continued strong order inflow and strong 1QFY07 ending order backlog of Rs393bn providing visibility for the next 2 years.

Our target P/E multiple of 23x FY08E is well below the historical high of 27.1x. A 27% CAGR in earnings over FY06-09E should support these valuations. We believe that BHEL can trade at a premium to the market given its strong earnings growth vis-à-vis the relative pedestrian earning growth of the BSE Sensex companies

Alternatively At our target price of Rs2,767, BHEL would trade at an EV/EBITDA multiple of 14.1x FY08E in line with that of Larsen & Toubro and Suzlon.

**Risk**: We rate BHEL Low Risk. The rating differs from the Medium Risk rating assigned by our quantitative risk rating system, which tracks 260-day historical share price volatility. We believe BHEL's current order book of Rs 393bn represents nearly 2 years sales and provides very good earnings visibility over the medium term.

1. Delay in power-sector reforms could affect order flows and earnings.

2. The sector could also be subject to regulatory uncertainties, which could affect sentiment and valuations on the stock.

3. Competitive pressures from global majors are also a concern; particularly as technology upgrades are affected. We believe it is imperative that BHEL demonstrate the ability to upgrade technology at reasonable costs for valuation ratings to sustain at current levels over the medium term.


4. Over the short-term investor progress on order flows does influence sentiment and delays herein could dampen sentiment.

# Appendix A-1

## **Analyst Certification**

We, Venkatesh Balasubramaniam and Deepal Delivala, research analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

## **IMPORTANT DISCLOSURES**



Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: ABB Ltd (India) and Bharat Heavy Electricals.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: ABB Ltd (India) and Bharat Heavy Electricals.

4

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citigroup Investment Research product ("the Product"), please contact Citigroup Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citigroup Investment Research Ratings Distribution			
Data current as of 31 December 2006	Buy	Hold	Sell
Citigroup Investment Research Global Fundamental Coverage (3106)	43%	41%	15%
% of companies in each rating category that are investment banking clients	45%	41%	34%
India Asia Pacific (118)	58%	14%	28%
% of companies in each rating category that are investment banking clients	48%	50%	39%

#### **Guide to Fundamental Research Investment Ratings:**

Citigroup Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citigroup Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

## **OTHER DISCLOSURES**

The subject company's share price set out on the front page of this Product is quoted as at 15 February 2007 04:00 PM on the issuer's primary market.

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to ABB Ltd (India). (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citigroupgeo.com.)

Citigroup Global Markets Inc. or its affiliates holds a long position in any class of common equity securities of ABB Ltd (India) and Bharat Heavy Electricals.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citigroup Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citigroup Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citigroup Investment Research does not set a predetermined frequency for publication, if the Product

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citigroup Wealth Advisors Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through

5

bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. If the Product was prepared by Citigroup Investment Research and distributed in Japan by Nikko Citigroup Ltd., it is being so distributed under license. Nikko Citigroup Limited is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Akasaka Park Building, 2-20, Akasaka 5-chome, Minato-ku, Tokyo 107-6122. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citigroup Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. Advice in the Product has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs.

© 2007 Citigroup Global Markets Inc. Citigroup Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm) is provided solely for your convenience and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

6

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST